Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15533767 | 0.82 | — | — | |
| SCHEMBL15533908 | 0.74 | TSHR (0.32) | TSHR | |
| SCHEMBL10287479 | 0.73 | CYP3A4 (0.36) | CYP3A4CYP2D6TSHRUSP2ALDH1A1 | |
| SCHEMBL2755099 | 0.72 | CYP2D6 (0.34) | CYP3A4CYP2D6TSHRUSP2ALDH1A1 | |
| SCHEMBL15533181 | 0.71 | — | — | |
| SCHEMBL24536722 | 0.70 | ALDH1A1 (0.34) | CYP3A4CYP2D6TSHRUSP2ALDH1A1 | |
| SCHEMBL20329284 | 0.70 | TSHR (0.35) | TSHR | |
| SCHEMBL21217092 | 0.69 | CYP2D6 (0.42) | CYP3A4CYP2D6TSHRUSP2ALDH1A1 | |
| SCHEMBL22279859 | 0.69 | CYP3A4 (0.36) | CYP3A4CYP2D6TSHRUSP2ALDH1A1 | |
| SCHEMBL165883 | 0.67 | CYP2D6 (0.42) | CYP3A4CYP2D6TSHRUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110082135-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME LLC | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082135-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CA, AKT1S1, AKT1 | CYP3A4 3065/4885CYP2D6 3866/4885TSHR 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.